Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.58 |
| ▸ | FNTB | P49356 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SQLE | Q14534 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28442015 | 0.98 | FNTA (0.56) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL15639480 | 0.88 | FNTA (0.68) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL30368929 | 0.87 | FNTA (0.62) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL30368947 | 0.87 | FNTA (0.62) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL29004811 | 0.87 | FNTA (0.62) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL940703 | 0.86 | FNTA (0.65) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL724992 | 0.86 | FNTA (0.65) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL11652143 | 0.85 | FNTA (0.59) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL8619861 | 0.80 | FNTA (0.77) | FNTAFNTBKMT2ASQLEMAPT | |
| SCHEMBL11049165 | 0.80 | FNTA (0.77) | FNTAFNTBKMT2ASQLEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | GGPS1, FNTA, GNPAT | FNTA 2/4885FNTB 6/4885KMT2A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.